Colorectal cancer remains a formidable clinical challenge, being one of the foremost causes of cancer mortality worldwide. Despite the revolutionary impact of immunotherapy in oncology, a significant subset of patients, especially those with treatment-resistant colorectal malignancies, fail to derive substantial benefit from existing immune checkpoint inhibitors. The Mount Sinai-led study elucidates that efficacious anti-tumor immunity requires more than mere activation of T lymphocytes; it necessitates the restoration of dynamic crosstalk between T cells and myeloid-derived suppressor cells within the tumor microenvironment.

Dr. Nina Bhardwaj, a leading immunotherapist and principal investigator on the study, emphasized the complexity of immune engagement. According to Dr. Bhardwaj, the conventional paradigm that focuses solely on T cell activation is insufficient. Instead, reestablishing communication channels between immune effectors allows for a coordinated and amplified anti-tumor response that can overcome established immunologic barriers posed by resistant colorectal cancers.

Employing state-of-the-art preclinical models and single-cell transcriptomic analysis, the research team dissected the heterogeneity of immunotherapy resistance. They identified a dual mechanism of immune evasion involving functionally exhausted T cells characterized by impaired effector capabilities, alongside the abundance of suppressive macrophages marked by TREM2 expression. These myeloid cells create an immunosuppressive niche that dampens T cell activity, thus enabling tumor persistence and progression.

To address this multifaceted resistance, the investigators devised a combinatorial immunotherapeutic regimen targeting multiple immune checkpoints—namely PD-1, CTLA-4, and LAG3—simultaneously with TREM2, which serves as a biomarker and functional node of immunosuppressive macrophage activity. This multiplexed targeting strategy is designed to concurrently reinvigorate exhausted T cells and reprogram macrophages, thereby restoring immune synergy within the tumor milieu.

Dr. Robert M. Samstein, co-senior author and immunologist, highlighted the necessity of a multi-pronged approach. By simultaneously addressing T cell dysfunction and mitigating macrophage-mediated suppression, this strategy transcends the limitations of single-agent therapies and opens avenues for treating a broader spectrum of colorectal cancer patients, including those with mismatch repair-proficient tumors typically refractory to immunotherapy.

Remarkably, preclinical evaluations demonstrated that this combination therapy achieved complete tumor clearance in experimental models of mismatch repair-deficient colorectal cancer, a subtype traditionally responsive to immunotherapy. Even more striking was the over 70 percent tumor eradication observed in mismatch repair-proficient models, underscoring the potential to overcome inherent resistance mechanisms.

The therapeutic approach achieves this by fundamentally rewiring the tumor microenvironment. Guillaume Mestrallet, the study’s primary author, explained that the dual immunomodulation effectively rejuvenates exhausted T cell populations while simultaneously dismantling the suppressive macrophage networks. This immune coordination culminates in robust and durable anti-tumor activity, representing a paradigm shift in cancer immunotherapy.

Beyond immediate tumor clearance, the study also revealed the induction of immune memory, a critical hallmark for long-term protection against relapse. This finding suggests that the therapy not only eliminates existing tumors but also primes the immune system to recognize and respond rapidly to potential future malignancies, providing hope for lasting remission in colorectal cancer patients.

These insights have profound implications for the future design of cancer immunotherapies. They underscore the importance of rationally engineered combination treatments that engage multiple facets of the immune system to circumvent complex resistance mechanisms. Such strategies could fundamentally change treatment outcomes for colorectal cancer and potentially other solid tumors exhibiting immunotherapy resistance.

The research was conducted in close partnership with colleagues at the University of California, San Francisco, and benefited from institutional funding at Mount Sinai along with grants including a National Institutes of Health training award. This collaborative effort exemplifies the power of interdisciplinary teamwork in translating scientific discoveries into clinical innovations.

As immunotherapy continues to evolve, the Mount Sinai team’s findings provide a compelling blueprint for next-generation therapeutic interventions, emphasizing the necessity of restoring immune cell crosstalk rather than relying on isolated immune activation. This study marks a critical step towards personalized, efficacious treatment paradigms for patients historically underserved by conventional therapies.

The research was detailed in the journal Cell Reports Medicine on May 5, 2026, offering a beacon of hope for advancing clinical strategies against one of the most challenging malignancies in oncology.

Subject of Research: Cells

Article Title: Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer

News Publication Date: 5-May-2026

Web References: http://dx.doi.org/10.1016/j.xcrm.2026.102786

Keywords: Colorectal cancer, Immunotherapy, T cells, Macrophages, Immune checkpoint inhibitors, TREM2, Tumor microenvironment, Immune resistance, Combination therapy

Tisagenlecleucel’s approval set a precedent for the integration of CAR T cell technologies in oncology, highlighting the potent efficacy of CD19-targeted immunotherapies in achieving durable remissions. Subsequent approvals followed, extending the reach of CAR T cells to include adult patients with various B cell malignancies, and spurring interest in expanding this modality to malignancies beyond the B lineage. However, despite these promising advancements, progress in developing additional CAR T cell therapies for other pediatric malignancies has been comparatively more limited. The complex biology of diseases such as acute myeloid leukemia (AML), T cell acute lymphoblastic leukemia, and solid tumors presents significant challenges to CAR T cell design and implementation.

One of the foremost hurdles in broadening CAR T cell applications lies in the heterogeneous antigen expression profiles among diverse malignancies, which undermines the specificity and persistence of engineered T cells. Unlike the relatively uniform and highly specific expression of CD19 on B lineage cells, AML and T cell leukemias demonstrate antigenic variability and overlap with normal hematopoietic cells, raising issues of on-target off-tumor toxicity. Furthermore, solid tumors and central nervous system malignancies pose formidable barriers including antigen heterogeneity, limited T cell infiltration, immunosuppressive tumor microenvironments, and physical obstacles such as the blood-brain barrier. These challenges have stalled the development of effective and safe CAR T products in these contexts, despite active preclinical and early clinical investigations.

The initial clinical trials and subsequent commercialization of CD19-targeted CAR T cells have laid the groundwork for understanding both the potential and limitations of this modality. Early experiences underscored critical aspects of safety management, such as the mitigation of cytokine release syndrome and neurotoxicity, which are unique to CAR T therapies. These toxicities necessitated the establishment of specialized treatment centers and rigorous monitoring protocols, shaping the infrastructure required to deliver these complex biologics safely. Additionally, insights into CAR T cell manufacturing, logistics, and product quality have refined approaches, although challenges related to scalability and cost remain.

In the pediatric and young-adult population, these therapies have not only offered a lifeline for patients with relapsed or refractory disease but have also demonstrated the feasibility of integrating gene-modified cell therapies into treatment pathways. Importantly, real-world data have revealed survival benefits unparalleled by conventional therapies, promoting earlier use of CAR T cells in treatment algorithms. Nevertheless, access to these life-saving treatments is constrained by multiple factors, including manufacturing bottlenecks, reimbursement issues, and disparities in care delivery, particularly across geographic and socioeconomic divides.

Current research efforts are intensifying the quest to push CAR T cell therapy beyond its established boundaries. Strategies to overcome antigen escape include the development of CAR T cells targeting multiple antigens simultaneously or sequentially, enhancing durability and reducing relapse. Moreover, refinement of CAR constructs to improve T cell fitness, trafficking, and resistance to tumor-mediated immunosuppression holds promise for extending efficacy to solid tumors and CNS malignancies. Gene editing technologies, such as CRISPR, are enabling the creation of allogeneic “off-the-shelf” CAR T cells, which could alleviate the manufacturing delays inherent in autologous therapies.

In parallel, the field is exploring combinatorial immunotherapies that incorporate CAR T cells with checkpoint inhibitors, oncolytic viruses, or other modulators of the tumor microenvironment to amplify anti-tumor responses. These combination approaches aim to address the multifactorial mechanisms of immune escape and tumor resistance that single-agent CAR T therapies cannot fully overcome. Clinical trial designs are evolving to test these novel paradigms, including adaptive trial frameworks that facilitate rapid iteration based on emerging data.

Safety considerations remain paramount as CAR T cells navigate increasingly complex biological environments. The potential for off-target effects, prolonged immunosuppression, and unforeseen toxicities necessitates ongoing surveillance and development of safety switches or “suicide” genes within CAR constructs. Additionally, understanding the long-term effects of CAR T cell persistence and integration is crucial, especially in pediatric patients who may face lifelong consequences.

From a clinical perspective, decision-making about the optimal use of CAR T cells involves a nuanced assessment of disease features, patient-specific factors, and alternative therapies. For instance, immunotherapies such as bispecific T cell engagers and antibody-drug conjugates are providing alternative or complementary options that may influence sequencing or combination strategies. Personalized approaches that integrate genomic, immunophenotypic, and microenvironmental data are anticipated to enhance patient selection and outcome prediction.

The economic implications of CAR T cell therapies are significant, with high upfront costs juxtaposed against potential long-term survival benefits and quality-of-life improvements. Health economics and policy frameworks must evolve to address reimbursement models, equitable access, and sustainable integration into healthcare systems worldwide. Furthermore, educational initiatives targeting clinicians, patients, and families are essential to optimize expectations and engagement in this rapidly advancing field.

As the CAR T cell field matures, researchers are gaining a deeper appreciation of the interplay between engineered cells and host immunity. Advances in single-cell analyses and systems immunology are elucidating mechanisms of resistance, immune modulation, and toxicity, guiding next-generation CAR designs. Integration of artificial intelligence and machine learning is accelerating the identification of novel targets and the optimization of manufacturing processes.

In summary, CAR T cell therapy represents a cornerstone of precision immuno-oncology for pediatric, adolescent, and young adult cancer patients. While the success of CD19-directed CAR T cells is unquestionable, the field is poised for transformative growth through innovation that addresses existing limitations and expands therapeutic horizons. Collaborative efforts among scientists, clinicians, regulatory bodies, industry, and patient advocates are essential to realize the full potential of CAR T cells and to democratize access globally.

The evolution of CAR T cell therapy encapsulates a paradigm shift in cancer treatment, one that harnesses the power of the immune system with unprecedented specificity and adaptability. Continuing research endeavors promise to unlock new frontiers, bringing hope to patients facing some of the most challenging malignancies of childhood and early adulthood. The future of CAR T cell therapy is not merely one of incremental improvements but of revolutionary breakthroughs that could redefine oncologic outcomes across diverse disease landscapes.

Subject of Research: CAR T cell therapy in pediatric, adolescent, and young adult cancer patients, focusing on applications, challenges, safety, access, and future developments.

Article Title: The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

Article References:
Schultz, L., McNerney, K., Lamble, A.J. et al. The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-025-01115-w

Image Credits: AI Generated

Stage III NSCLC represents a particularly challenging clinical scenario characterized by locally advanced tumors often deemed unresectable, with a high risk of both local failure and distant metastasis. Conventional treatment strategies have typically relied on concurrent chemo-radiotherapy, which, despite representing the current standard of care, yields suboptimal long-term survival outcomes. The APOLO trial builds upon significant advancements in immunotherapy, particularly immune checkpoint inhibitors, which have revolutionized cancer treatment over the past decade by empowering the patient’s own immune system to recognize and eradicate malignant cells.

The rationale behind the APOLO regimen lies in the synergistic potential of combining chemotherapy and immunotherapy as induction treatment, designed to debulk tumor burden and prime the immune microenvironment before administering definitive chemo-radiotherapy. This multimodal sequence is then followed by maintenance immunotherapy to sustain immune surveillance and suppress residual disease. Preliminary evidence suggested that such an approach could much more effectively overcome the tumor microenvironment’s immunosuppressive barriers, thereby enhancing durable responses and long-term survival.

In this tightly designed phase 2 study, patients with stage III NSCLC first received induction chemo-immunotherapy, which typically involved platinum-based chemotherapy in combination with an immune checkpoint inhibitor targeting the PD-1/PD-L1 axis. The goal was to exploit chemotherapy’s immunomodulatory effects—such as increasing tumor antigen release and enhancing dendritic cell maturation—while simultaneously activating T-cell mediated immunity via checkpoint blockade. Following this induction phase, subjects underwent standard concurrent chemotherapy with thoracic radiotherapy, aiming to eradicate the primary tumor and involved lymph nodes.

What sets the APOLO trial apart is its strategic incorporation of maintenance immunotherapy immediately after completion of chemo-radiotherapy. This continuous immune awakening intends to maintain cytotoxic T cell activity over time, reducing risk of both local relapse and distant metastasis. The trial meticulously monitored efficacy parameters such as progression-free survival, overall survival, and objective response rates, alongside thorough safety profiling to gauge tolerability of this intensive combined regimen.

The findings from the APOLO trial are highly encouraging—participants experienced notably improved response rates and prolonged progression-free intervals compared to historical controls receiving chemo-radiotherapy alone. Remarkably, the integration of immunotherapy in both induction and maintenance phases was well-tolerated, with adverse events consistent with known profiles of checkpoint inhibitors and chemotherapy agents. Importantly, no new safety signals emerged, highlighting the feasibility of this complex therapeutic strategy in a clinical setting.

Mechanistically, the study provides incisive insights into the tumor immune microenvironment dynamics. Analysis revealed enhanced infiltration of cytotoxic CD8+ T cells and reduction of immunosuppressive regulatory T cells following induction therapy, suggesting effective immune priming. Moreover, radiotherapy appeared to synergize by inducing immunogenic cell death, releasing tumor neoantigens that further stimulate the adaptive immune system, thus cloaking the residual tumor in an immunologically ‘hot’ milieu conducive to sustained checkpoint blockade efficacy.

This concept of ‘priming and boosting’ the immune response through sequential chemo-immunotherapy followed by definitive chemo-radiotherapy and maintenance immunotherapy represents a paradigm shift in managing locally advanced lung cancer. By leveraging the complementary mechanisms of each therapeutic component, the APOLO trial advances the notion that timing and sequencing are critical to optimizing anti-tumor immunity and achieving durable tumor control.

The implications extend beyond lung cancer, as this multimodal regimen challenges conventional silos of medical oncology, radiation oncology, and immunotherapy. It underscores the necessity of integrating personalized immunologic profiling and biomarker-driven patient selection to identify those most likely to benefit from such intensively tailored treatments. In addition, APOLO’s blueprint raises provocative questions about combining novel agents, such as next-generation immune modulators or targeted therapies, at various stages of the regimen for further enhancements.

From a clinical standpoint, APOLO offers hope to patients facing stage III NSCLC, a disease entity long associated with dismal outcomes and high morbidity. The prospect of a more effective, yet tolerable treatment algorithm aligns with the urgent need for strategies that extend survival, preserve quality of life, and ultimately increase the number of cures. Furthermore, ongoing follow-up will be essential to define long-term survival benefits, late toxicity manifestations, and potential resistance mechanisms emerging from this complex therapeutic interplay.

In conclusion, the phase 2 APOLO trial represents a seminal advancement in precision oncology for stage III NSCLC. By demonstrating the safety and enhanced efficacy of an induction chemo-immunotherapy strategy followed by chemo-radiotherapy and immunotherapy maintenance, this study offers a robust framework for future large-scale trials and potential changes in treatment guidelines. It exemplifies the tremendous promise of harnessing the immune system’s power alongside conventional modalities to rewrite the narrative of a deadly disease.

As the oncology community eagerly anticipates the results of ongoing and future phase 3 studies validating APOLO’s findings, the integration of immunotherapy into early treatment phases of lung cancer heralds a new era of innovation and hope. The intricate choreography between chemotherapy, radiotherapy, and immunotherapy invites a rethinking of how multifaceted cancer treatments can be optimized to outsmart tumor adaptation and immune evasion. Ultimately, APOLO charts a course toward transformation—turning the tide against stage III NSCLC and illuminating pathways forward for other malignancies driven by immune resistance.

Subject of Research: Treatment of stage III non-small cell lung cancer (NSCLC) using a combined chemo-immunotherapy and chemo-radiotherapy approach followed by immunotherapy maintenance.

Article Title: Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.

Article References:
Provencio, M., Campos, B., Guirado, M. et al. Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial. Nat Commun 16, 10124 (2025). https://doi.org/10.1038/s41467-025-66097-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-66097-w

This innovative vaccine leverages nanoliposomes, which are tiny vesicles made from lipids that can encapsulate therapeutic agents. By employing nanoliposomes, the researchers not only enhance the stability of the vaccine components but also facilitate targeted delivery to cancerous cells. This targeted approach holds the promise of reducing systemic side effects often associated with conventional cancer therapies. The vaccine is specifically designed to include P53, WT1, and CA125 epitopes, which are known to provoke immune responses against ovarian cancer cells.

The P53 protein is widely regarded as a tumor suppressor, and its mutations are often implicated in various cancers, including ovarian cancer. By using P53-derived peptides in the vaccine, researchers aim to stimulate the immune system to recognize and attack cells harboring these mutations. Concurrently, the WT1 protein has been identified as a neoantigen expressed in many ovarian tumors, making it another prime target for vaccination strategies. The incorporation of CA125, a well-known biomarker for ovarian cancer, adds an additional layer of specificity, aligning the immune response more closely with the disease.

Moreover, the study rigorously assessed the efficacy of the vaccine through a series of preclinical trials. In these trials, the vaccine demonstrated the capability to elicit a robust immune response in animal models, which is a crucial determinant of its potential effectiveness in humans. The results revealed an increased presence of T cells specifically targeting ovarian cancer cells, which is indicative of an active immune response. This finding alone marks a pivotal step forward, suggesting that a peptide vaccine can stimulate a sufficient immune response to combat the disease effectively.

The therapeutic context of this peptide vaccine is particularly relevant given the current landscape of ovarian cancer treatments. Traditional methods, including surgery, chemotherapy, and radiotherapy, often fail to provide long-term remission for patients. The use of personalized medicine, particularly immunotherapy, is gaining traction as it tailors treatments to the individual patient’s cancer profile. The incorporation of peptide-based vaccines into this treatment paradigm could bridge the gap, offering a promising adjunct to existing therapies.

Additionally, the safety profile of peptide vaccines is generally favorable compared to other forms of treatment. With fewer adverse effects, patients could experience an improved quality of life during treatment, an important consideration in any oncological strategy. The researchers emphasized that ongoing monitoring and studies will continue to assess the long-term safety and efficacy of their vaccine, as the ultimate goal remains to ensure both survivability and quality of life for ovarian cancer patients.

The potential impact of this research extends beyond ovarian cancer alone. It opens new avenues for the application of nanoliposome technology in other forms of cancer treatment, creating a ripple effect that could enhance therapeutic options across the spectrum of oncology. By proving the effectiveness of a multi-epitope peptide vaccine, the study sets a precedent for similar approaches targeting other tumor-associated antigens in various cancers.

Indubitably, the multi-faceted approach adopted by this research not only addresses the specific needs of ovarian cancer but also reflects a broader, more comprehensive understanding of cancer as a disease that requires targeted, personalized therapeutic strategies. As the research community shifts its focus towards immunotherapy, studies like this become pivotal in developing the next generation of cancer treatments.

In conclusion, the innovative use of nanoliposomes combined with the strategic selection of tumor-specific epitopes represents a significant advance in the field of cancer immunotherapy, particularly for ovarian cancer. The promising results from the preclinical trials pave the way for future clinical applications, potentially transforming the therapeutic landscape for patients suffering from this devastating disease. As researchers continue to unravel the complexities of the immune system and its interactions with cancer, it’s crucial that such pioneering studies be supported and expanded upon, offering hope to countless individuals affected by cancer.

The journey of this peptide vaccine is just beginning, and it will be captivating to observe how it evolves in future clinical settings. The integration of cutting-edge science with a compassionate approach to patient care sets the stage for remarkable advancements in the fight against cancer.

Subject of Research: Vaccine Development Against Ovarian Cancer

Article Title: Development and assessment of a peptide vaccine against ovarian cancer utilizing nanoliposomes loaded with P53, WT1, and CA125 epitopes.

Article References:

Shariati, F., Hashemi, M., Peyvandi, M. et al. Development and assessment of a peptide vaccine against ovarian cancer utilizing nanoliposomes loaded with P53, WT1, and CA125 epitopes.
J Ovarian Res (2025). https://doi.org/10.1186/s13048-025-01792-2

Image Credits: AI Generated

DOI: 10.1186/s13048-025-01792-2

Keywords: Ovarian cancer, peptide vaccine, nanoliposomes, immunotherapy, P53, WT1, CA125, apoptosis, tumor markers, personalized medicine, cancer immunotherapy.

The systematic literature review conducted by Ajani, Wang, Nikolaidis, and colleagues shines a spotlight on the critical role of Tislelizumab in treating patients who have previously failed other treatment modalities. ESCC, known for its aggressive nature and poor prognosis, often leaves patients with limited treatment choices once first-line therapies have been exhausted. The introduction of Tislelizumab presents a hope for better management of this challenging condition.

In the study, researchers meticulously reviewed multiple clinical trials and studies that evaluated the efficacy of Tislelizumab in patients with advanced ESCC. The findings reveal a noteworthy achievement in overall survival rates when compared to traditional treatments. These findings not only contribute to understanding Tislelizumab’s performance but also underscore the burgeoning importance of immunotherapies in oncology today.

An essential aspect of the review was the emphasis on safety profiles. While efficacy is of utmost importance, safety must equally be prioritized, especially in a patient population that may already be significantly weakened by cancer and prior treatments. The results suggest that Tislelizumab has a favorable safety profile, with manageable adverse effects compared to chemotherapy regimens, which are often burdensome and contribute to decreased quality of life.

Furthermore, the simulation models applied in the study allowed researchers to project long-term treatment outcomes and cost-effectiveness, further evidencing the potential advantages of Tislelizumab in real-world settings. Economic analyses are critical in today’s healthcare landscape, as they not only aid in clinical decision-making but also help policy-makers prioritize funding for innovative treatments. The promising results from these models underscore Tislelizumab’s potential to not only improve survival rates but also offer a more sustainable treatment option financially.

Additionally, the immune checkpoint inhibition mechanism of Tislelizumab deserves critical admiration. By blocking programmed cell death protein 1 (PD-1), this treatment restores the immune system’s ability to recognize and attack cancer cells, a significant shift away from cytotoxic therapies that indiscriminately target all rapidly dividing cells. This specificity may be a pivotal factor in the enhanced efficacy and tolerability noted in patients receiving Tislelizumab.

Such breakthroughs, however, do bring forth discussions regarding biomarker utilization. Identifying which patients are more likely to benefit from Tislelizumab therapy is an ongoing challenge. The authors have pointed out the need for further investigations to establish predictive markers that could aid in patient selection, maximizing treatment efficacy and minimizing unnecessary exposure to inadequate regimens. This area of research could revolutionize personalized medicine in oncology, tailoring therapies to individual patient profiles.

Moreover, the review highlights the importance of understanding the broader implications of introducing Tislelizumab into existing treatment algorithms. As more therapies become available, oncologists must adeptly navigate the complexities of combination therapies. The interplay between Tislelizumab and existing treatment modalities could provide synergistic effects, leading to improved outcomes and enhanced patient survival prospects.

Importantly, the role of patient feedback and quality of life assessments in treatment planning cannot be overlooked. Patients’ perspectives are vital in comprehensively evaluating the impact of new therapies. Insights gathered from patient experiences concerning Tislelizumab could provide crucial information that influences future therapeutic strategies and enhances shared decision-making processes in oncology clinics.

In summary, the systematic literature review underscores Tislelizumab’s promise as an effective second-line therapy for esophageal squamous cell carcinoma, combining efficacy, safety, and the potential for improved quality of life for patients. The ongoing research in this domain represents a beacon of hope, paving the way for future innovations and treatment strategies that recognize the pivotal role of the immune system in combating cancer. As we continue to unravel the complexities of this disease, the findings regarding Tislelizumab herald a new chapter in the quest for comprehensive and effective cancer care.

As researchers and clinicians alike sift through the data, it becomes increasingly evident that the future of oncology may lie in harnessing the body’s own immune defenses through therapies like Tislelizumab. The challenge now is not merely to develop more treatments but to ensure they reach those who will derive the most benefit. This review serves as an essential contribution to that evolving knowledge base.

In conclusion, patients with esophageal squamous cell carcinoma may soon have renewed optimism, as treatments like Tislelizumab promise not only to prolong life but also to improve the quality of that life. Continued research, collaboration, and an unwavering commitment to innovation will ultimately shape the future of cancer therapy, propelling us towards outcomes that were once thought to be unattainable.

Subject of Research: Esophageal Squamous Cell Carcinoma (ESCC) and Tislelizumab Treatment

Article Title: Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons

Article References: Ajani, J.A., Wang, K., Nikolaidis, G.F. et al. Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons. Adv Ther (2025). https://doi.org/10.1007/s12325-025-03410-5

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12325-025-03410-5

Keywords: Tislelizumab, esophageal squamous cell carcinoma, immunotherapy, efficacy, safety, clinical trials, biomarkers, treatment comparison, survival rates, patient quality of life.

Among the solid tumours, central nervous system (CNS) malignancies present even greater challenges. CNS tumours are often associated with devastating prognoses and lack of effective therapies, particularly in paediatric populations. The presence of the blood–brain barrier (BBB) restricts the infiltration of therapeutic agents and immune cells into the CNS. Moreover, concerns over potential neurotoxicity raise complex questions about dosing and safety. Yet despite these formidable hurdles, a growing body of preclinical and clinical research suggests that CAR T cell therapy can provide meaningful clinical benefit for some patients with CNS tumours.

Recent clinical trials, conducted in both adult and paediatric cohorts with primary CNS malignancies such as glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG), have demonstrated promising signals of efficacy. These trials have employed unique strategies to enhance CAR T cell delivery, persistence, and activity within the CNS microenvironment. For example, local delivery approaches including intraventricular or intracavitary administration circumvent the BBB and facilitate direct exposure of CAR T cells to tumour cells. These trials have highlighted not only therapeutic potential but also key safety considerations, underscoring the importance of balancing efficacy and minimizing neurotoxic side effects.

One fundamental obstacle to CAR T cell success in CNS tumours is their limited persistence and expansion following infusion. Unlike hematologic cancers that circulate in lymphatic tissues or blood, CNS tumours tend to be highly immunosuppressive, secreting cytokines such as transforming growth factor-beta (TGF-β) and promoting regulatory T cell subsets that dampen immune activity. Additionally, the dense extracellular matrix and abnormal vasculature within CNS tumours create physical barriers to T cell infiltration. Engineering strategies to enhance CAR T cell durability—including the incorporation of co-stimulatory domains that optimize T cell activation and survival—are therefore critical areas of ongoing research.

The immunosuppressive TME in CNS malignancies not only constrains CAR T cell function but also creates avenues for immune escape. Tumour cells can downregulate or alter antigen expression, effectively evading CAR recognition. Researchers are exploring multi-specific CAR constructs capable of targeting multiple antigens simultaneously to counteract antigen heterogeneity and loss. Furthermore, combining CAR T cells with checkpoint blockade therapies or agents that modulate the microenvironment holds promise to restore and sustain potent antitumour responses.

Another transformative area involves the modulation of CAR T cell trafficking to ensure robust homing to CNS tumours. Preclinical models demonstrate that the chemokine milieu within CNS tumours can be manipulated to attract CAR T cells expressing corresponding chemokine receptors. This approach may be further enhanced by transient modulation or disruption of the BBB to facilitate systemic administration. Investigations into nanotechnology and biomaterial scaffolds aim to provide controlled local delivery of CAR T cells while reducing systemic exposure and toxicity.

Neurotoxicity remains a significant clinical concern when deploying immune therapies in the CNS. Conditions such as neuroinflammation, edema, and cytokine release syndrome (CRS) can have catastrophic consequences. Emerging clinical data emphasize the importance of vigilant monitoring protocols and the development of “off-switch” mechanisms—such as suicide genes or pharmacologically controllable CAR constructs—that allow rapid abrogation of CAR T cell activity in the event of adverse effects.

Despite challenges, early-phase trials in pediatric and adult patients offer encouraging evidence. Target antigens like EGFR variant III (EGFRvIII), IL13 receptor alpha 2 (IL13Rα2), and HER2 have been leveraged in CAR designs, each with varying degrees of success in reducing tumour burden and prolonging survival. A handful of patients have achieved durable responses, exemplifying the potential of this modality to change the natural history of otherwise fatal CNS cancers.

The clinical application of CAR T cells in CNS malignancies also motivates exciting advancements in manufacturing processes. Autologous CAR T cell production requires time and resources, frequently delaying treatment initiation. Novel approaches to accelerate manufacturing, or to develop allogeneic “off-the-shelf” CAR T cells, could broaden access and reduce costs, an imperative for patients with rapidly progressing CNS disease.

An equally important direction lies in the integration of CAR T therapy within multimodal treatment regimens. Combining CAR T cells with radiation, chemotherapy, or targeted agents may synergize immune activation while debulking tumours and modulating the tumour microenvironment. Investigating optimal sequencing and combinations remains a priority to maximize therapeutic index and patient outcomes.

Looking to the future, ongoing and anticipated clinical trials are expanding the scope of CAR T cell therapy for CNS tumours. These include studies with next-generation CAR designs incorporating novel co-stimulatory molecules, synthetic biology approaches for enhanced target specificity, and gene-editing techniques to render CAR T cells resistant to immunosuppressive signals. The dynamic interplay between technological innovation and clinical need is driving a new era of personalized immunotherapy in neuro-oncology.

Ultimately, the development of CAR T cells for CNS malignancies epitomizes the complexity and promise of immunotherapy in solid tumours. The road ahead demands multidisciplinary collaboration across immunology, neurology, oncology, and bioengineering. Each incremental advancement not only deepens fundamental understanding but also offers hope for patients facing some of the most aggressive and lethal cancers.

As the field continues to evolve, transparency in reporting clinical outcomes, adverse events, and mechanistic insights will be paramount. Harnessing big data analytics, artificial intelligence, and integrative biomarker discovery can enable predictive models for patient selection and response monitoring. These tools will be crucial in realizing the full potential of CAR T cells to become transformative therapies extending beyond hematological malignancies to address the unmet needs in CNS cancer.

In conclusion, while substantial obstacles remain, the momentum generated by preclinical innovation and early clinical success supports a cautiously optimistic outlook for CAR T cell therapy in CNS tumours. Sustained investment in research, coupled with thoughtful trial design and patient-centered care, will dictate the pace at which this groundbreaking modality reshapes the therapeutic landscape for one of oncology’s most intractable challenges.

Subject of Research: Development and clinical application of chimeric antigen receptor (CAR) T cell therapy for central nervous system (CNS) malignancies.

Article Title: The development of CAR T cells for patients with CNS malignancies.

Article References:
Binder, Z.A., Bagley, S.J., Foster, J.B. et al. The development of CAR T cells for patients with CNS malignancies. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01102-1

Image Credits: AI Generated

Small cell lung cancer accounts for approximately 15% of all lung cancer cases and is characterized by rapid progression and early metastasis, notably to the liver. Liver metastasis (LM) in SCLC severely compromises patient prognosis, with conventional treatment modalities offering limited survival benefits. Historically, chemoimmunotherapy—a combination of cytotoxic chemotherapy and immune checkpoint inhibitors—has represented the frontline approach. However, despite advances in this therapeutic combination, median survival remains dismally low, prompting the need for novel treatment enhancements.

The innovation of low-dose radiotherapy involves delivering localized irradiation at doses substantially lower than those used in conventional radical radiotherapy. Typically, LDRT administers radiation in the range of 1 to 5 gray (Gy), contrasting starkly with the 20 to 60 Gy doses standard in curative settings. This relatively gentle radiation dose does not aim for direct tumor ablation but rather exploits radiobiological mechanisms that can modulate the tumor microenvironment, potentially enhancing the immune system’s ability to target malignant cells.

The retrospective study analyzed data from 74 SCLC patients with liver metastases treated at a single institution between September 2019 and September 2024. These patients were divided into two cohorts: those receiving chemoimmunotherapy alone and those receiving chemoimmunotherapy in conjunction with LDRT. By applying Kaplan-Meier survival analysis and Cox proportional hazards regression, the researchers meticulously compared progression-free survival (PFS) and overall survival (OS) between these groups, also accounting for variables such as line of therapy and extent of metastatic spread.

Results from this rigorous analysis revealed that patients who received LDRT alongside chemoimmunotherapy had a statistically significant improvement in median progression-free survival, extending to 5.1 months compared to 4.0 months in the chemoimmunotherapy-only group. This improvement was consistent across various patient subgroups, indicating a robust benefit of integrating LDRT in diverse clinical scenarios. Importantly, prolonging progression-free survival suggests that LDRT effectively delays disease progression, a crucial factor in patient management.

While improvements in progression-free survival were broadly observed, enhancements in overall survival were more nuanced. The study elucidated that the survival advantage of combining LDRT with chemoimmunotherapy was most pronounced in patients receiving later-line therapies. In this subgroup, the median overall survival nearly doubled, reaching 11.0 months versus 6.0 months in patients treated with chemoimmunotherapy alone. This finding suggests that LDRT may play a crucial role in overcoming therapy resistance commonly encountered in subsequent treatment lines.

The underlying biological rationale for LDRT’s effectiveness centers on its immunomodulatory properties. Low-dose radiation can prime the immune system by inducing tumor antigen release, promoting dendritic cell activation, and enhancing T-cell infiltration into tumor tissues. This immunogenic modulation complements the mechanism of immune checkpoint inhibitors included in chemoimmunotherapy, which reinvigorate anti-tumor immune responses. The synergistic interplay between LDRT-induced immune activation and immunotherapy could therefore underpin the observed clinical benefits.

Moreover, LDRT is associated with a favorable safety profile compared to high-dose radiotherapy, minimizing damage to surrounding healthy tissues. This aspect is especially vital for patients with liver metastasis, where the integrity of hepatic function critically influences treatment tolerance and overall health status. By delivering targeted, low-intensity radiation, LDRT mitigates the risk of radiation-induced liver injury, thereby maintaining patients’ eligibility for ongoing systemic therapies.

This study also explored the heterogeneity of treatment response by stratifying patients based on the number of metastatic organs involved. Although most subgroups exhibited improved progression-free survival with LDRT, the influence on overall survival was more variable, underscoring the complexity of advanced SCLC’s systemic dissemination. Tailoring LDRT incorporation based on individual disease burden could optimize therapeutic outcomes in future clinical applications.

Despite its retrospective design and limited sample size, this investigation offers crucial insights into the potential of LDRT to transform the therapeutic landscape for a traditionally refractory cancer subset. The findings advocate for prospective clinical trials to validate these results and elucidate optimal treatment schedules, dosing parameters, and patient selection criteria to maximize the utility of LDRT in conjunction with chemoimmunotherapy.

The implications of this study extend beyond survival metrics. Integrating LDRT with chemoimmunotherapy may enhance patients’ quality of life by delaying disease progression and potentially reducing symptom burden associated with hepatic metastases. Improved disease control can translate into prolonged intervals of functional well-being, a paramount goal in managing advanced cancers where curative prospects remain elusive.

In summary, this study underscores the promise of low-dose radiotherapy as a potent adjunct to existing chemoimmunotherapy regimens for small cell lung cancer patients with liver metastasis. The approach leverages radiobiological principles to modulate the tumor microenvironment and augment immune-mediated tumor eradication. As oncology moves toward more personalized and multimodal therapies, such innovative combinations could redefine standard care and improve patient outcomes in this challenging disease.

Future research trajectories should aim to explore the molecular mechanisms underlying LDRT’s immunomodulatory effects in SCLC, identify biomarkers predictive of response, and evaluate the combination’s efficacy in a broader range of metastatic sites. By harnessing the synergistic potential of radiation and immunotherapy, the oncology community may pave the way for novel, more effective interventions against metastatic small cell lung cancer.

Ultimately, the integration of low-dose radiotherapy with chemoimmunotherapy offers a beacon of hope in an area of significant unmet medical need. As evidence accrues, this promising strategy may soon be adopted widely, providing tangible survival benefits and improved quality of life for patients suffering from one of the most aggressive forms of lung cancer with liver metastasis.

Subject of Research:
Small cell lung cancer patients with liver metastasis treated with low-dose radiotherapy combined with chemoimmunotherapy.

Article Title:
Low-dose radiotherapy combined with chemoimmunotherapy yields superior survival outcomes compared with chemoimmunotherapy alone for patients with small cell lung cancer with liver metastasis: a retrospective study.

Article References:
Zhang, Y., Li, W., Zhang, W. et al. Low-dose radiotherapy combined with chemoimmunotherapy yields superior survival outcomes compared with chemoimmunotherapy alone for patients with small cell lung cancer with liver metastasis: a retrospective study. BMC Cancer 25, 1785 (2025). https://doi.org/10.1186/s12885-025-15212-7

DOI:
19 November 2025

Image Credits: Scienmag.com

Acute lymphoblastic leukemia, particularly the B-cell subtype characterized by CD22 positivity and Philadelphia chromosome negativity, has long posed formidable treatment challenges in patients over 60 years of age. Traditional cytotoxic chemotherapy regimens frequently culminate in excessive morbidity and mortality within this cohort, attributable to diminished physiological reserves and heightened treatment-related complications. Against this backdrop, the Alliance A041703 Cohort 1 trial sought to evaluate the efficacy and tolerability of targeted immunotherapeutic agents as a standalone front-line treatment, eschewing classical chemotherapy altogether.

The trial enrolled 33 patients ranging from 60 to 84 years old, all newly diagnosed with B-cell ALL, ensuring strict eligibility based on molecular and hematologic criteria. Participants were administered up to two induction cycles of inotuzumab ozogamicin, a CD22-directed antibody-drug conjugate conjugated to a potent cytotoxic agent, designed to selectively bind and deliver lethal payloads to malignant blasts. Following this, patients received four or five cycles of blinatumomab, a bispecific T-cell engager (BiTE) antibody that recruits cytotoxic T lymphocytes to CD19-expressing leukemia cells, thereby mediating precise immunologic eradication.

The synergy between these agents capitalizes on their distinct mechanisms: inotuzumab ozogamicin initiates substantial leukemic cell reduction by targeted cytotoxicity, while blinatumomab sustains and deepens remission through immune system activation and clearance of residual disease. This sequential approach addresses the limitations inherent in monotherapy and mitigates the toxicities associated with intensive chemotherapy.

Remarkably, the study demonstrated a complete remission rate of 97%, an outcome that dramatically surpasses historical benchmarks for this fragile population. At a median follow-up of one year, 75% of participants remained alive and relapse-free, with an overall survival rate of 85%. These statistics signal a paradigm shift, emphasizing that older adults with aggressive leukemias can achieve durable remission and extended survival absent conventional chemotherapy’s severe adverse effects.

Beyond efficacy, tolerability was a critical endpoint. The regimen exhibited a manageable safety profile, with adverse events consistent with known drug-related toxicities but generally less severe than those observed with standard chemotherapy protocols. Importantly, over half the patients were able to complete the entire treatment course, suggesting feasibility in an elderly population with typically significant comorbidities.

Notably, the trial included patients with prior malignancies such as multiple myeloma and breast cancer, often excluded from clinical trials due to concerns over compounded immunosuppression and organ dysfunction. The comparable response rates in this subgroup underline the regimen’s broad applicability and robustness even in medically complex cases.

This clinical trial’s implications extend beyond immediate therapeutic gains; it provides a conceptual framework for precision medicine in leukemia care. By tailoring treatment modalities based on specific tumor antigen profiles and leveraging immunologic mechanisms, clinicians can transcend age-related treatment limitations, thereby enhancing quality of life and survival outcomes.

The growing prominence of antibody-based treatments and bispecific engagers in hematology highlights an evolutionary leap in cancer immunotherapy. Unlike nonspecific cytotoxic therapies, these agents promote targeted destruction of malignant cells while sparing normal hematopoietic and organ tissues, thus reducing systemic toxicity and improving patient tolerability. Their integration into front-line regimens may redefine standards of care for older adults diagnosed with ALL and potentially other hematological malignancies.

While the current study showcases compelling data, the authors emphasize the necessity of further validation in larger, randomized trials to confirm these findings and optimize dosing strategies. Additionally, exploration into combinatorial approaches with emerging cellular therapies or novel immune modulators may amplify therapeutic efficacy and durability.

This research, supported by the National Cancer Institute through the National Clinical Trials Network and underpinned by grants from Pfizer and Amgen, underscores the collaborative efforts driving innovation in cancer treatment. The Alliance for Clinical Trials in Oncology continues to spearhead clinical investigations that reshape oncologic therapeutics by bridging groundbreaking science with patient-centered care.

In conclusion, the Alliance A041703 Cohort 1 study heralds a transformative approach to treating older adults afflicted with difficult-to-treat B-cell ALL, illustrating that immunotherapy regimens tailored to leukemia-specific antigens can achieve remarkable remission and survival outcomes independent of traditional chemotherapy. This milestone advances the promise of personalized cancer therapy and offers hope for improved prognosis in an age group historically underserved in clinical oncology.

Subject of Research: People

Article Title: Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results

News Publication Date: 30-Sep-2025

Web References:
– Alliance A041703 clinical trial: https://www.clinicaltrials.gov/study/NCT03739814
– Journal of Clinical Oncology publication: https://ascopubs.org/doi/10.1200/JCO-25-00307

References:
– Wieduwilt MJ, et al. Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025 Sep 30; DOI: 10.1200/JCO-25-00307.

Image Credits: Wake Forest School of Medicine

Keywords: Cancer, Leukemia, B-cell Acute Lymphoblastic Leukemia, Immunotherapy, Targeted Therapy, Inotuzumab Ozogamicin, Blinatumomab, Hematologic Oncology, Clinical Trial, Personalized Medicine, Elderly Cancer Patients, CD22-positive B-cell ALL

A cornerstone of this body of work is a rigorous epidemiological study investigating the relationship between lifetime alcohol consumption and colorectal cancer risk. Conducted in collaboration with the National Cancer Institute, this research leveraged data from the landmark Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). The analyses revealed that adults consistently consuming an average of 14 or more alcoholic drinks weekly exhibited a 25% elevated risk of developing colorectal cancer compared to those consuming less than a single drink per week throughout adulthood. This heightened risk was particularly pronounced for rectal cancer, underscoring the need for targeted public health messaging and risk stratification based on drinking patterns across the lifespan.

This study harnessed advanced statistical modeling to adjust for confounders such as age, sex, smoking status, and dietary factors, thereby isolating alcohol consumption as an independent variable influencing colorectal neoplasia development. The findings suggest mechanistic pathways by which ethanol metabolites, such as acetaldehyde, may induce DNA damage and promote tumorigenesis within colorectal tissues. Moreover, chronic alcohol exposure is known to disrupt intestinal mucosal immunity and microbial composition, further exacerbating carcinogenic potential. These insights provide a compelling rationale for integrating lifetime alcohol consumption metrics into risk assessment tools for colorectal cancer screening programs.

In a separate vein of translational research, the UMGCCC team advanced therapeutic modalities targeting relapsed or refractory acute myeloid leukemia (AML). They reported preliminary results from a Phase I clinical trial administering CRD3874-SI, an allosteric small molecule agonist of the STimulator of INterferon Genes (STING) pathway, via intravenous infusion. The STING pathway plays a critical role in innate immune sensing and activation, eliciting potent antitumor immune responses by promoting type I interferon production and enhancing antigen presentation. This trial marks a novel clinical application of STING agonists to overcome immune evasion mechanisms characteristic of aggressive AML phenotypes.

Early-phase safety data from this trial revealed manageable toxicity profiles and initial signals of clinical activity, supporting dose escalation and further evaluation. The trial enrolled patients with refractory disease who had undergone multiple prior treatment regimens, emphasizing the unmet need for effective interventions in this population. Molecular biomarkers and peripheral immune cell analyses are ongoing to characterize the immunomodulatory effects of CRD3874-SI and optimize dosing strategies. These findings highlight the exciting potential of innate immune stimulators as adjuncts or alternatives to conventional chemotherapy and targeted agents in hematologic malignancies.

Complementing these immunotherapy advances, researchers also reported on differential efficacy and safety profiles of chimeric antigen receptor (CAR) T-cell therapies in multiple myeloma patients. Their comparative analysis focused on two FDA-approved CAR T-cell constructs: ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel). These autologous T-cell therapies have revolutionized treatment paradigms for refractory myeloma by redirecting cytotoxic T cells against B-cell maturation antigen (BCMA) expressed on malignant plasma cells. However, real-world data capturing expansion kinetics, phenotypic characteristics, functional potency, and toxicities remain critical to refining patient selection and management.

The UMGCCC team utilized longitudinal immunophenotyping and cytokine profiling to delineate divergent expansion patterns between cilta-cel and ide-cel infused cells. Cilta-cel demonstrated prolonged persistence and a more polyfunctional T-cell phenotype, correlating with enhanced antitumor efficacy. Conversely, ide-cel exhibited more rapid expansion but was associated with a distinct cytokine release syndrome (CRS) spectrum. These nuanced differences inform clinical decision-making regarding balancing therapeutic benefit against risk of neurotoxicity and CRS, two prevalent adverse effects limiting CAR T-cell therapy utility.

The implications of these findings are manifold. For epidemiologists and clinicians, integrating lifetime behavioral exposure data such as alcohol consumption into predictive modeling can sharpen early detection strategies for colorectal cancer. For oncologists and immunologists, emerging data from STING agonist trials open avenues to amplify innate immune pathways against hematological cancers resistant to standard therapies. For hematology-oncology specialists, dissecting CAR T-cell therapy nuances empowers precision medicine approaches to maximize efficacy while mitigating treatment-related toxicities in multiple myeloma.

Moreover, these investigations collectively underscore the importance of multidisciplinary collaboration bridging molecular biology, clinical trials, and population health. By leveraging large cohort studies alongside cutting-edge immunotherapeutic trials, the UMGCCC and its partners exemplify a translational research paradigm aimed at swiftly converting scientific insights into patient-centered innovations. As immunotherapies diversify and cancer epidemiology evolves in response to lifestyle factors, such comprehensive research endeavors will be quintessential in shaping next-generation oncology care.

The research community eagerly awaits further data releases from these trials, particularly regarding long-term survival outcomes, immune correlates of response, and biomarker-driven patient stratification models. These forthcoming insights will be critical to elucidating mechanisms of resistance, optimizing combination therapies, and expanding indications for novel agents like STING agonists beyond AML. Concurrently, public health interventions informed by epidemiologic data on alcohol and cancer risk stand to reduce incidence and improve population-level outcomes.

In essence, the findings presented by the UMGCCC researchers at AACR 2025 represent a tapestry of scientific rigor and clinical innovation strategically poised to impact cancer prevention, diagnosis, and treatment. Their work highlights the intricate interplay between lifestyle determinants and immunological therapies in influencing cancer trajectories. As these research directions continue to mature, they hold promise for optimizing individualized care pathways and ultimately enhancing the quality and duration of life for cancer patients.

As a final note, the synergy between alcohol-related cancer risk assessment and immunotherapy development exemplifies the multifactorial nature of oncology that demands both epidemiological vigilance and therapeutic ingenuity. It is through such comprehensive and technically nuanced investigations that the medical community can hope to stay ahead of cancer’s complexity and heterogeneity, paving the way for a future where cancer burden is sustainably diminished.

Subject of Research: Cancer Epidemiology and Immunotherapy Innovations; Colorectal Cancer Risk; STING Agonist Therapy for AML; CAR T-cell Therapy Optimization in Multiple Myeloma

Article Title: University of Maryland Researchers Present Groundbreaking Cancer Epidemiology and Immunotherapy Advances at AACR 2025

Web References:

• https://www.umms.org/umgccc
• https://www.medschool.umaryland.edu/
• https://www.aacr.org/meeting/aacr-annual-meeting-2025/
• https://www.cancer.gov/
• https://prevention.cancer.gov/major-programs/prostate-lung-colorectal-and-ovarian-cancer-screening-trial-plco
• https://www.abstractsonline.com/pp8/#!/20273/presentation/10591
• https://www.abstractsonline.com/pp8/#!/20273/presentation/2148

Keywords: Cancer research, Colorectal cancer, Cancer treatments, Clinical studies